IRAK4 and Alzheimer disease: As already noted, KT-474 did reduce circulating inflammatory biomarkers in AD as well as in HS and impacted clinical endpoints in both diseases, pointing to a role for IRAK4 in the pathogenesis of inflammation in both diseases.